Publications by authors named "Virginia Stauffer"

Claim this Profile
A
A Conceptual Model of Patient Experiences of Painful Diabetic Peripheral Neuropathy to Support Clinical Outcomes Assessment.
Karolina Schantz, Rikki Mangrum, Rebecca L Robinson, Virginia L Stauffer, John D Markman

J Pain Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Content Validity of the Modified Neuropathy Total Symptom Score-6 Self-Administered (mNTSS-6-SA) in a Painful Diabetic Peripheral Neuropathy Population.
Heather Gerould, Rikki Mangrum, Rebecca L Robinson, Karolina Schantz, Alexandra Bryant, Virginia L Stauffer

J Pain Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-country Discrete Choice Experiment.
Jaein Seo, Caitlin Thomas, Tommi Tervonen, Nicolas Krucien, Janet H Ford, Virginia L Stauffer

Neurol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study.
Jaein Seo, Charlie A Smith, Caitlin Thomas, Tommi Tervonen, Asha Hareendran, Virginia L Stauffer

Patient· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm.
Leslie Citrome, Margarita Sánchez Del Rio, Yan Dong, Russell M Nichols, Antje Tockhorn-Heidenreich, Virginia L Stauffer

Adv Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti

J Headache Pain· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis.
Virginia L Stauffer, Tina M Oakes, Mallikarjuna Rettiganti, Kathleen A Day, Angelo Camporeale

J Neurol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
Jakub Jedynak, Eric Eross, Astrid Gendolla, Mallikarjuna Rettiganti, Virginia L Stauffer

J Headache Pain· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
David W Dodick, Erin G Doty, Sheena K Aurora, Dustin D Ruff, Virginia L Stauffer

Cephalalgia· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
Janet H Ford, Virginia L Stauffer, Peter McAllister, Sreelatha Akkala, Matthew Sexson

Qual Life Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
Janet H Ford, Virginia L Stauffer, Peter McAllister, Sreelatha Akkala, Matthew Sexson

Qual Life Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti

J Headache Pain· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.
Virginia L Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day

J Headache Pain· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine.
Virginia L Stauffer, Shufang Wang, Jo Bonner, ByungKun Kim, Rohit Bhandari

BMC Neurol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Mark E Bangs, David Kudrow, Shufang Wang, Tina M Oakes, Gisela M Terwindt, Virginia L Stauffer

BMC Neurol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Mark E Bangs, David Kudrow, Shufang Wang, Tina M Oakes, Gisela M Terwindt, Virginia L Stauffer

BMC Neurol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Stephen D Silberstein, Virginia L Stauffer, Katie A Day, Sarah Lipsius, Maria-Carmen Wilson

J Headache Pain· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
Virginia L Stauffer, Shufang Wang, Menelaos Voulgaropoulos, Vladimir Skljarevski, Amy Kovacik

Headache· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Stephen D Silberstein, Virginia L Stauffer, Katie A Day, Sarah Lipsius, Maria-Carmen Wilson

J Headache Pain· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Stefanie Förderreuther, Qi Zhang, Virginia L Stauffer, Sheena K Aurora, Miguel J A Láinez

J Headache Pain· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
Angelo Camporeale, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke, Virginia L Stauffer

BMC Neurol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine.
Janet H Ford, Shonda A Foster, Virginia L Stauffer, Dustin D Ruff, Sheena K Aurora

Patient Prefer Adherence· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Virginia L Stauffer, David W Dodick, Qi Zhang, Jeffrey N Carter, Jessica Ailani

JAMA Neurol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies.
Virginia L Stauffer, Ryan Sides, Michel Lanteri-Minet, William Kielbasa, Yan Jin

Patient Prefer Adherence· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?
Virginia L Stauffer, Peng Liu, Celine Goldberger, Lauren B Marangell, Craig Nelson

J Clin Psychiatry· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis